Related Experiment Video
Updated: Aug 11, 2025
11:44
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
7.7K
LncRNA LOC285758 Induced Non-Small Cell Lung Cancer Development through Up-Regulating CDK6 by Sponge Adsorption of
Xiangtao Yu1, Dianjun Liu1, Lin Wang2
1Department of Pharmacy, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong Province, 264000, China.
Iranian Journal of Public Health
|February 6, 2023
Summary
Long non-coding RNA LOC285758 promotes non-small cell lung cancer (NSCLC) progression by regulating the miRNA-204/CDK6 axis. Targeting this pathway could offer new therapeutic strategies for NSCLC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Non-coding RNAs (ncRNAs) play a crucial role in the pathogenesis and progression of non-small cell lung cancer (NSCLC).
- Identifying novel therapeutic targets within ncRNAs is essential for advancing NSCLC treatment strategies.
Purpose of the Study:
- To investigate the role of long non-coding RNA (lncRNA) LOC285758 in NSCLC.
- To elucidate the molecular mechanisms underlying LOC285758's function in NSCLC progression.
- To evaluate LOC285758 as a potential therapeutic target for NSCLC.
Main Methods:
- Gene knockout of LOC285758 in NSCLC cell lines (A549 and H292) to assess phenotypic effects.
- Investigation of the regulatory relationship between LOC285758, miRNA-204, and its downstream target CDK6.
- Examination of the impact of miRNA-204 overexpression and CDK6 knockout on NSCLC cell behavior.
Main Results:
- LOC285758 expression was significantly upregulated in NSCLC tissues and cells.
- Knockout of LOC285758 inhibited NSCLC cell survival and migration.
- LOC285758 repressed miRNA-204, which in turn targeted CDK6. Overexpression of miRNA-204 or knockout of CDK6 suppressed NSCLC cell invasion, survival, and migration.
- The effects of LOC285758 knockout were reversible by inhibiting miRNA-204, leading to increased CDK6 and LOC285758 expression.
Conclusions:
- The lncRNA LOC285758/miRNA-204/CDK6 axis is a key regulator of NSCLC cell migration and survival.
- This axis represents a potential therapeutic target for non-small cell lung cancer.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
01:06Induced Pluripotent Stem Cells
4.2K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.2K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K